Published in AIDS Weekly, June 9th, 2003
"The ability to induce broadly neutralizing antibodies should be a key component of any forthcoming vaccine" against HIV, noted Ralph Pantophlet and colleagues at the Scripps Research Institute in La Jolla, California. However, "one potential vaccine candidate, monomeric gp120, has generally failed to elicit such antibodies."
A hyperglycosylated gp120 mutant preferentially bound to a broadly neutralizing antibody, and could form the basis for a more effective vaccine, Pantophlet and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.